Scientific paper - Original scientific paper
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies
Frontiers in Immunology, 11 (2021); 613954. https://doi.org/10.3389/fimmu.2020.613954

Tomaszewska, Agnieszka; Jagasia, Madan; Beohou, Eric; van der Werf, Steffie; Blaise, Didier; Kanfer, Edward; Milpied, Noel; Reményi, Péter; Ciceri, Fabio; Bourhis, Jean H.; Chevallier, Patrice; Solano, Carlos; Socié, Gerard; Bruno, Benedetto; Rambaldi, Alessandro; Castagna, Luca; Kröger, Nicolaus; Corradini, Paolo; Afanasyev, Boris; Ladetto, Marco; Niederwieser, Dietger; Scheid, Christof; Sengeloev, Henrik; Kroschinsky, Frank; Yakoub-Agha, Ibrahim; Schoemans, Helene; Koenecke, Christian; Penack, Olaf; Perić, Zinaida; Greinix, Hildegard; Duarte, Rafael F.; Basak, Grzegorz W. More authors...

Cite this document

Tomaszewska, A., Jagasia, M., Beohou, E., van der Werf, S., Blaise, D., Kanfer, E. ... Basak, G. W. (2021). Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. Frontiers in Immunology, 11.. doi: 10.3389/fimmu.2020.613954

Tomaszewska, Agnieszka, et al. "Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies." Frontiers in Immunology, vol. 11, 2021. https://doi.org/10.3389/fimmu.2020.613954

Tomaszewska, Agnieszka, Madan Jagasia, Eric Beohou, Steffie van der Werf, Didier Blaise, Edward Kanfer, Noel Milpied, et al. "Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies." Frontiers in Immunology 11 (2021). https://doi.org/10.3389/fimmu.2020.613954

Tomaszewska, A., et al. (2021) 'Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies', Frontiers in Immunology, 11. doi: 10.3389/fimmu.2020.613954

Tomaszewska A, Jagasia M, Beohou E, van der Werf S, Blaise D, Kanfer E, and sur.. Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. Frontiers in Immunology [Internet]. 2021 February [cited 2024 October 08];11. doi: 10.3389/fimmu.2020.613954

A. Tomaszewska, et al., "Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies", Frontiers in Immunology, vol. 11, February 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:878916. [Accessed: 08 October 2024]

Please login to the repository to save this object to your list.